calculation (LDL-C Fried ), which is the most commonly used procedure in clinical laboratories for the estimation of LDL-C, is the routine method recommended by the NCEP Working Group on Lipoprotein Measurement (6, 7 ) . Although the latter method correlates highly with the ␤-quantification, it has several shortcomings (8 ) : it is invalid when a specimen is collected in the nonfasting state or from a patient with type III hyperlipoproteinemia, or in the presence of increased triglycerides (TGs Ͼ4000 mg/L). Furthermore, because this calculation requires the determination of three different measurements [TC, TGs, and HDL-cholesterol (HDL-C)], each with its own analytical CV, it may not always meet the performance criteria of total error Յ12% established by the NCEP. Therefore, the NCEP Working Group on Lipoprotein Measurement recommended the development of direct methods for LDL-C measurement (7 ) . A new homogeneous assay for the determination of LDL-C has been developed recently and is being introduced by Roche Diagnostics (LDL-C Roche ; Roche Diagnostics, Indianapolis, IN) (9 ) . The goal of this multicenter study was to evaluate the analytical and clinical performance of this new assay.
Materials and Methods samples
Fresh serum samples (n ϭ 355) were obtained, after an overnight fast, at three centers for the patient correlation studies. Paired serum samples, one obtained after 12-h fasting and another 3.5 h after a high-fat meal (ϳ32 g of fat), were collected from 43 healthy subjects to determine the postprandial effect on the measurement of LDL-C by this direct homogeneous method. In addition, 29 freshfrozen human serum samples were sent to seven laboratories in the United States and Europe, where the homogeneous LDL-C Roche assay was performed using the Roche/Hitachi 704, 911, 912, or 917 analyzers. These samples were characterized by the LDL-C CRMLN method at Northwest Lipid Research Laboratories in Seattle, WA, a Cholesterol Reference Method Laboratory Network (CRMLN) Laboratory.
lipid measurements TC and TGs were determined enzymatically with the CHOD-PAP (cat. no. 450061; Roche Diagnostics) and GPO-PAP (cat. no. 1488872; Roche Diagnostics) methods, respectively, according to the manufacturer's specifications. The day-to-day imprecision of the two methods, reflected by the CV when Precinorm ® L and Precipath ® HDL/LDL controls were used, was Ͻ3%. HDL-C was measured using a homogeneous assay (cat. no. 1930672; Roche Diagnostics) (10 -13 ) . HDL-C was measured with a day-to-day CV of Ͻ3%.
ldl-c roche assay
At neutral pH (pH 7.0) and in the presence of MgCl 2 , sulfated ␣-cyclodextrin, and dextran sulfate, the enzymatic reaction for cholesterol in VLDL and chylomicrons is markedly reduced (reagent 1, cat. no. 1985604; Roche Diagnostics). The nonionic detergent in reagent 2, which selectively solubilizes LDL-C but not HDL-C, enables the measurement of LDL-C by a conventional enzymatic reaction (9 ) . The assay was calibrated as recommended with the Calibrator for automated systems (C.f.a.s.) LDL-C Plus calibrator, which is standardized to the CRMLN reference method, and performed according to the manufacturer's recommendation.
␤-quantification (ldl-c uc )
An accurately measured volume of serum was place into an ultracentrifugation tube, overlayed with sufficient 0.15 mol/L NaCl to fill the tube, and centrifuged at 105 000g for 18 h at 10°C in Baltimore and St. Louis. In Boston, ultracentrifugation was performed at 250 000g for 3 h at 10°C. The floating layer containing VLDL and chylomicrons (if present) was removed, and the infranatant was reconstituted to known volume and analyzed for cholesterol using the enzymatic cholesterol assay. LDL-C UC was calculated as the difference between the cholesterol concentration of the infranatant and HDL-C, measured by dextran sulfate precipitation in Boston and St. Louis and by homogeneous assay in Baltimore. All three laboratories that performed the ␤-quantification are certified by the CDC National Heart, Lung and Blood Institute Lipid Standardization Program (TC, TG, HDL-C) and two of them participate in the Alert Proficiency Survey (Pacific Biometrics Research Foundation, Seattle, WA) to periodically check the accuracy of the ␤-quantification procedure. The LDL-C concentrations of the 29 samples involved in the interlaboratory survey were determined by the CRMLN Method (LDL-C CRMLN ), which uses a heparin/Mn 2ϩ precipitation with subsequent cholesterol determination by the Abell-Kendall method.
ldl-c fried LDL-C Fried (6 ) was calculated using the following equation:
after excluding samples with TGs Ͼ4000 mg/L. [TG]/5 is an estimate of VLDL-C. All concentrations are in mg/L (6 ).
linearity
Human LDL concentrates (Scantibodies, Inc.) were serially diluted with 9 g/L NaCl at 11 different concentrations by the eight participating laboratories. The predicted values were calculated by a regression line according to Passing and Bablok, using LDL-C Roche concentrations up to 4000 mg/L (14 ) .
interferences
Interferences from hemoglobin and bilirubin were determined according to Glick et al. (15 ) . In addition, isolated VLDL and chylomicrons were added to different pooled 
method comparison
In three laboratories, the LDL-C Roche assay and the LDL-C Fried were compared with the LDL-C UC . A total of 355 fresh sera were analyzed in parallel. In addition, the influences of increasing concentrations of LDL-C UC and TGs on the LDL-C Roche assay were examined by bias plots using the 355 samples mentioned above. To account for the interlaboratory biases of the lipid determinations in the three laboratories, the data were adjusted to CDC reference values using the results of CDC National Heart, Lung and Blood Institute Lipid Standardization Program Part III measurements made in the three laboratories during the study period January 1998 through March 1998). In each laboratory, four different samples for the lipid measurements of TC, TGs, and HDL-C were analyzed 18 times. The biases for TC, TGs, and HDL-C were calculated for each sample, using the differences of the results by the CDC and each laboratory; the mean biases for TC, TGs, and HDL-C were then calculated for each laboratory. The mean biases were Ϫ43 to 17 mg/L for TC, Ϫ12 to 24 mg/L for TGs, and 2-11 mg/L for HDL-C, respectively.
The adjustments of the data were then calculated specifically for each laboratory. The adjustments for LDL-C UC and LDL-C Fried were performed according to the following equations:
These adjusted data were used for all analyzes.
precision study
Two commercial control sera, with low and high LDL-C concentrations, and two human serum pools were used to assess the precision of the new homogeneous LDL-C assay in eight laboratories, according to the NCCLS EP5-T protocol (16 ) .
postprandial study
In this study, the effect of feeding on the determination of LDL-C concentration by the Roche assays was examined in paired samples from 43 subjects.
storage of samples
Fresh serum samples (n ϭ 125) were assayed using the LDL-C Roche assay immediately after collection and after storage at Ϫ20°C for up to 12 months in a noncycling freezer to determine the effect of storage on the measurement of LDL-C Roche . In addition, the short-term storage up to 14 days at 4°C was also examined using two serum pools.
statistical methods
Regression analyses were performed using the method of Passing and Bablok (14 ) . Total error was calculated as the sum of the systematic error plus random error (17, 18 ) . Systematic error was calculated from the linear regression equation y c ϭ bx c ϩ a, where b is the slope of the regression line, and a is the y-axis intercept (LDL-C UC vs LDL-C Roche ). At an LDL-C concentration of x c , systematic error was the absolute value of y c Ϫ x c . Random error was 1.96 ϫ CV, based on the run-to-run precision study. Results were considered statistically significant at P Ͻ0.05. The positive predictive value (PPV) of an LDL-C assay at each specified cut-point was calculated as: [true positive/ (true positive ϩ false positive)] ϫ 100, where "true positive" means that the LDL-C results of both the comparison procedure (LDL-C UC ) and the test method (LDL-C Roche or LDL-C Fried ) were greater than or equal to the cutoff concentration, and "false positive" means that the test method LDL-C result was greater than the cut-point when the reference procedure LDL-C value was less than the cut-point. The negative predictive value (NPV) of an LDL-C assay at each specified cut-point was calculated as [true negative/(true negative ϩ false negative)] ϫ 100, where "true negative" means that the LDL-C results of both the reference procedure and the test method were less than the cut-point concentration, and "false negative" means that the test method LDL-C result was less than the cut-point when the reference procedure LDL-C value was greater than or equal to the cut-point concentration.
Results

analytical performance
Two lyophilized control sera (Precinorm L and Precipath HDL/LDL) and two human serum pools, prepared by the individual sites, were used to assess the imprecision of the LDL-C Roche assay in all eight participating laboratories. No difference in the reproducibility was observed between the lyophilized controls and the human serum pools. The mean total CVs at LDL-C concentrations of ϳ700 mg/L (human serum pool 1), 950 mg/L (Precinorm L), 1300 mg/L (human serum pool 2), and 2100 mg/L (Precipath L) were between 0.7% and 3.1% (Table 1) and did not vary significantly with concentration. (Fig. 1) . For the row data, the equations of the regression lines according to Passing and Bablok were: y ϭ 1.042x Ϫ 124.2 mg/L (r ϭ 0.961; n ϭ 355; 95% CI, 1.011-1.072 for the slope, and Ϫ158.4 to 81.1 mg/L for the y-intercept) for the LDL-C Roche assay; and y ϭ 1.024x Ϫ 66.5 mg/L (r ϭ 0.973; n ϭ 313; 95% CI, 1.002-1.046 for the slope, and Ϫ6.9 to 38.0 mg/L for the y-intercept) for the LDL-C Fried assay (data not shown). In these method comparisons, the LDL-C Fried concentrations were included only for those samples with TG concentrations Ͻ4000 mg/L. To better illustrate the performance of the LDL-C Roche assay in hypertriglyceridemic samples, specimens with TG concentrations Ͻ4000 mg/L and those with TG concentrations Ն4000 mg/L were compared separately with the 
concentration difference plots
The concentration differences of the homogeneous LDL-C Roche assay from LDL-C UC and LDL-C Fried from LDL-C UC were examined as a function of either increased LDL-C UC or TGs. In samples with TG concentrations Ͻ4000 mg/L, the LDL-C Roche assay and the LDL-C Fried showed a relatively constant mean negative bias of Ϫ60 and Ϫ30 mg/L, respectively, independent of the LDL-C UC concentration. In samples with TG concentrations Ն4000 mg/L, the scattering of LDL-C Roche was comparable to the results of samples with TG concentrations Ͻ4000 mg/L, whereas the concentration differences increased tremendously for LDL-C Fried (Fig. 2, A and B) . The negative bias of the LDL-C Roche assay increased slightly from a mean of Ϫ56 mg/L at a TG concentration of 1000 mg/L to a mean of Ϫ82 mg/L at a TG concentration of 10 000 mg/L. The mean bias of Ϫ30 mg/L of LDL-C Fried was only marginally influenced by increasing TG concentrations up to 4000 mg/L. However, this negative bias increased dramatically in samples with TG concentrations Ն4000 mg/L: up to more than Ϫ500 mg/L at a TG concentration of 10 000 mg/L (Fig. 2, C and D) .
total error
The systematic error of the LDL-C Roche assay at various LDL-C concentrations, encompassing the clinical decision cut-points (1000 -1900 mg/L), ranged from 0.8% to 6.3% ( Table 2 ). The random error was always Ͻ4%, as recommended by the NCEP (7 ). This assay fulfilled the current NCEP total error requirements for LDL-C at the clinical decision cut-point range. 
interlaboratory survey
The LDL-C Roche values of the 29 fresh-frozen serum samples reported by seven participating laboratories were compared with those obtained by the LDL-C CRMLN method (Table 3) . Means, standard deviations (Ϯ 1 SD), and ranges for TC, TGs, HDL-C, and LDL-C CRMLN were 2186 Ϯ 381 (1290 -2950), 1313 Ϯ 788 (520 -3510), 529 Ϯ 160 (303-973), and 1427 Ϯ 348 (690 -2080) mg/L, respectively. The slopes and y-intercepts of the regression lines according to Passing and Bablok were comparable. All of the slopes were Ͼ1, whereas the y-intercepts were negative. The mean biases ranged from Ϫ12 to 72 mg/L. When the imprecision from these measurements was calculated, the interlaboratory CVs of the samples were on average 2.5%, with a range of 1.7-4.4%. These findings confirm the good agreement among the seven laboratories in the measurement of the LDL-C Roche assay, regardless of the type of the Roche/Hitachi analyzer used.
interferences
Hemoglobin at a concentration of 6000 mg/L caused a positive bias in the LDL-C Roche assay by ϳ10% (data not shown). Unconjugated and conjugated bilirubin added to serum pools up to concentrations of 500 and 250 mg/L, respectively, showed a tendency to decrease the LDL-C Roche value by Ͻ5% (data not shown). Isolated VLDL and chylomicrons, which were added to serum pools at different concentrations, showed a negative bias slightly Ͼ10% when the TG concentration exceeded 10 000 mg/L (data not shown).
classification of patients according to ncep guidelines
The LDL-C Roche assay and the LDL-C Fried method were compared for their ability to appropriately classify patients into treatment groups as established by the NCEP (Fig. 3) (4 ) . For this purpose, the UC method used in the three laboratories involved in the method comparison, adjusted to CDC reference values, was considered the reference method. In those subjects with LDL-C below 1000 and 1300 mg/L, 96% were classified correctly using the LDL-C Roche assay. In those with LDL-C concentrations of 1300 -1600 and Ͼ1600 mg/L, 68 -81% of subjects were classified correctly by the homogeneous method. The LDL-C Fried correctly classified a slightly higher percentage of subjects than the homogeneous method. It is important to note, however, that with the Friedewald method, only those samples with TG concentrations Ͻ4000 mg/L were included in the analysis. In those with LDL-C Ͼ1900 mg/L, both methods classified at least 89% of subjects correctly.
The effects of TGs on the classification of subjects into NCEP cut-points, using both the LDL-C Roche and LDL-C Fried methods, are presented in Table 4 . The classification in samples with TG concentrations of Ͻ2000 mg/L and 2000 -4000 mg/L was slightly better when the LDL-C Fried was used (88.6% vs 85.3% and 92.9% vs 88.9%). In samples with TG concentrations Ͼ4000 mg/L, for which the Friedewald calculation could not be used, the percentage of correctly classified subjects by the LDL-C Roche was nearly perfect (97.5% for TG concentrations of 4000 -6000 mg/L, and 100.0% for TG concentrations Ͼ6000 mg/L).
ppv and npv
The ability of the LDL-C Roche assay to correctly classify subjects at the medical decision cut-points was evaluated in this study population (n ϭ 355), using the LDL-C UC concentrations as the true values. For the interest of comparison, the PPV and NPV of LDL-C Fried were also examined using only those subjects with TG concentrations Ͻ4000 mg/L (n ϭ 313). The PPV of LDL-C estimated by either method decreased as LDL-C concentrations a Correlation coefficients and regression lines for the homogeneous assay vs the LDL-C CRMLN method were calculated using the nonparametric method described by Passing and Bablok (14 ) . b Hi, Hitachi. c Significantly different from unity: P Ͻ0.05.
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increased (PPV range, 91-100% for LDL-C Roche assay and 90 -99% for LDL-C Fried ; Fig. 4A ). In contrast, the NPV of LDL-C estimated by either method increased as LDL-C concentrations increased (NPV range, 80 -99% for LDL-C Roche assay and 81-99% for LDL-C Fried ; Fig. 4B ). The PPVs were similar for both methods, whereas the NPV was slightly better for the LDL-C Fried assay.
postprandial study 
Discussion
Numerous epidemiological studies and prospective clinical trials have demonstrated that an increased LDL-C concentration is an important independent risk factor for CHD. In addition, the reduction of increased LDL-C is a major goal for the primary and secondary prevention of CHD (2, 3, 19 ) . The Friedewald calculation for estimating the LDL-C concentration is the routine method currently recommended by the NCEP Working Group for Lipoprotein Measurement. Because of the shortcomings of this calculation, methods for the direct determination of LDL-C are needed (7 ) . Homogeneous methods have the apparent advantage of obviating the need for pretreatment of samples, being performed online, and requiring only a few microliters of sample. The purpose of this multicenter study was to evaluate the analytical and clinical performance of the recently introduced liquid homogeneous LDL-C Roche method. The NCEP recommends that the total error for LDL-C determination be Ͻ12%, which can be achieved by an imprecision of Յ4% and a bias from the reference method of Յ4% (7 ). The imprecision criterion was met by all eight laboratories that participated in this study, whereas the bias exceeded 4% at different LDL-C concentrations. This bias tended to increase with decreasing LDL-C concentrations. Because the imprecision seen was low, this homogeneous assay met the NCEP total error requirements in the range of the clinical decision cut-points.
Good agreement was seen between the LDL-C Roche and the LDL-C UC procedures. The bias plots revealed a constant negative bias that was independent of the LDL-C UC concentration. In samples with TG concentrations Ն4000 mg/L, this negative bias was slightly accentuated when the LDL-C Roche assay was used. However, the negative bias of LDL-C Fried was much more pronounced in such samples, so that this method is obsolete in samples with TG concentrations Ն4000 mg/L, as already published by Friedewald himself (6 ) . In addition, the results of the method comparisons further support that the homogeneous LDL-C Roche assay can be used in the determination of LDL-C in hypertriglyceridemic samples. Therefore, the LDL-C Roche assay provides laboratorians the means to measure LDL-C in samples with increased TGs. The UC method measures the cholesterol component of the widedensity LDL fraction, which includes LDL, intermediate density lipoprotein, and lipoprotein(a). The good agreement between the UC procedure and this homogeneous assay suggests that the latter is capable of measuring the cholesterol content of the broad density LDL fraction. However, the constant negative bias seen between the LDL-C Roche and the UC may be an indication of a suboptimal standardization of the new homogeneous LDL-C Roche assay.
The effects of common interferents were investigated by addition experiments and bias plots using the serum samples included in the method comparison study. Addition experiments showed no significant interference caused by free hemoglobin up to concentrations of at least 6000 mg/L and unconjugated or conjugated bilirubin up to 500 and 250 mg/L, respectively. Different addition experiments with isolated TG-rich lipoproteins showed deviations of Ͼ10% for LDL-C Roche values when TGs exceeded 10 000 mg/L. A slight but incremental negative bias in LDL-C Roche was also apparent from the bias plot as TG concentrations increased. Although this method enables the determination of LDL-C in samples with TG concentrations Ͼ4000 mg/L, the LDL-C results tended to decrease with increasing TG values, whereas an earlier reported homogeneous method tended to increase (20 ).
According to the NCEP-ATP II guidelines, the management of hyperlipidemic patients, using either dietary or drug therapy, is based on four LDL-C cut-points (1000, 1300, 1600, or 1900 mg/L). LDL-C concentrations determined by either the LDL-C Roche assay or the adjusted LDL-C Fried correctly classified 86% and 89% of the subjects, respectively, into the above mentioned cut-points. The LDL-C Roche assay was able to correctly classify into NCEP cut-points nearly all subjects with TG concentrations Ն4000 mg/L, samples in which the Friedewald LDL should not be applied. This will provide the clinical laboratory the ability to measure LDL-C in hypertriglyceridemic samples and alleviate the need for the expensive, time-consuming, cumbersome UC procedure. Furthermore, our data indicate that the LDL-C Roche assay is effective in classifying subjects into NCEP cut-points when samples collected postprandially are used.
Our data show that storage at Ϫ20°C for up to 12 months did not influence the measurement of samples with TG concentrations Ͻ10 000 mg/L. However, in turbid samples with TG concentrations Ͼ10 000 mg/L, unacceptable overestimation of the LDL-C concentration (Ͼ1000 mg/L) was seen. Therefore, this assay is not adequate for use in grossly lipemic samples stored frozen at Ϫ20°C. In addition, our data indicate that samples stored at 4°C for up to 2 weeks did not experience any change in their LDL-C concentrations when measured by the homogeneous assay. This observation could have a practical importance to the clinical laboratory.
In conclusion, the homogeneous LDL-C Roche assay is precise and acceptably accurate. It represents an improvement in the measurement of LDL-C concentration in samples with increased TGs or samples collected postprandially and may assist in the identification of individuals at increased risk of CHD and the management of patients with hyperlipoproteinemia.
